CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced that its Chief Executive Officerย John Climacoย will present at theย LSX World Congress 2024. Climaco is slated to present at 4:15 PM (GMT+1) on Monday, April 29, 2024, at the event taking place in London, England. In addition to the presentation, CNSP announced that its management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
To view the full press release, visitย https://ibn.fm/lCPun.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The companyโs lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (โGBMโ), an aggressive and incurable form of brain cancer. For more information, visit the companyโs website atย www.CNSPharma.com.
NOTE TO INVESTORS:ย The latest news and updates relating to CNSP are available in the companyโs newsroom atย https://ibn.fm/CNSP
About TinyGems
TinyGemsย is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text โGemsโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published:ย https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered byย IBN
